340 related articles for article (PubMed ID: 9673391)
21. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
23. p53, mdm-2, and p21 waf-1 in the porokeratoses.
Nelson C; Cowper S; Morgan M
Am J Dermatopathol; 1999 Oct; 21(5):420-5. PubMed ID: 10535569
[TBL] [Abstract][Full Text] [Related]
24. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
25. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations.
Dowell SP; McGoogan E; Picksley SM; el-Deiry WS; Vogelstein B; Hall PA
Cytopathology; 1996 Oct; 7(5):340-51. PubMed ID: 8911758
[TBL] [Abstract][Full Text] [Related]
26. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
27. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Droller MJ
J Urol; 2001 May; 165(5):1811-2. PubMed ID: 11345951
[No Abstract] [Full Text] [Related]
28. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Uchida T; Gao JP; Wang C; Jiang SX; Muramoto M; Satoh T; Minei S; Shimura S; Irie A; Kameya T; Baba S
Urology; 2002 Apr; 59(4):615-20. PubMed ID: 11927338
[TBL] [Abstract][Full Text] [Related]
30. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of cyclin G1 and p21WAF1/CIP1 in neurons following transient forebrain ischemia: comparison with early DNA damage.
van Lookeren Campagne M; Gill R
J Neurosci Res; 1998 Aug; 53(3):279-96. PubMed ID: 9698156
[TBL] [Abstract][Full Text] [Related]
32. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
34. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
35. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas.
Kanavaros P; Stefanaki K; Vlachonikolis J; Eliopoulos G; Kakolyris S; Rontogianni D; Gorgoulis V; Georgoulias V
Histol Histopathol; 2000 Apr; 15(2):445-53. PubMed ID: 10809363
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
[TBL] [Abstract][Full Text] [Related]
37. p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years.
Regezi JA; Dekker NP; McMillan A; Ramirez-Amador V; Meneses-Garcia A; Ruiz-Godoy Rivera LM; Chrysomali E; Ng IO
Oral Oncol; 1999 Jul; 35(4):379-83. PubMed ID: 10645402
[TBL] [Abstract][Full Text] [Related]
38. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice.
Bouvard V; Zaitchouk T; Vacher M; Duthu A; Canivet M; Choisy-Rossi C; Nieruchalski M; May E
Oncogene; 2000 Feb; 19(5):649-60. PubMed ID: 10698510
[TBL] [Abstract][Full Text] [Related]
39. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
40. p53, WAF1/CIP1 and mdm2 expression in skin lesions associated with human papillomavirus and human immunodeficiency virus.
Arany I; Yen A; Tyring SK
Anticancer Res; 1997; 17(2B):1281-5. PubMed ID: 9137486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
